This article describes the kinetic modeling of [ 11 C]-harmine binding to monoamine oxidase A (MAO-A) binding sites in the human brain using positron emission tomography (PET). Positron emission tomography studies were performed in healthy volunteers at placebo conditions and after treatment with clinical doses of moclobemide. In either condition, a two-tissue compartment model (2CM) provided better fits to the data than a one-tissue model. Estimates of k 3 /k 4 values from an unconstrained 2CM were highly variable. In contrast, estimates of the specifically bound radioligand distribution volume (DV B ) from an unconstrained 2CM were exceptionally stable, correlated well with the known distribution of MAO-A in the brain (cerebellum ofrontal cortexEputamen otemporal cortexEcingulate othalamus) and thus provided reliable indices of MAO-A density. Total distribution volume (DV) values were also highly stable and not different from those estimated with the Logan approach. Fixing the DV of free and nonspecifically bound radiotracer (DV F þ NS ) or coupling DV F þ NS between brain regions enabled more stable estimates of k 3 /k 4 as compared with an unconstrained 2CM. Moclobemide treatment leads to a 64% to 79% MAO-A blockade across brain regions, a result that supports the specificity of [ 11 C]-harmine binding to MAO-A. The stability and reliability of DV B values obtained from an unconstrained 2CM, together with the computational simplicity associated with this method, support the use of DV B as an appropriate outcome measure for [ 11 C]-harmine. These results indicate the suitability of using [ 11 C]-harmine for quantitative evaluation of MAO-A densities using PET and should enable further studies of potential MAO-A dysregulation in several psychiatric and neurologic illnesses.
Introduction
Monoamine oxidase (MAO) is a mitochondrial enzyme which catalyzes the oxidative deamination of biogenic amines. In the brain, MAO is responsible for the metabolic inactivation of dopamine, noradrenaline, and serotonin and thus plays a central role in the regulation of these neurotransmitter levels. In mammals, two isoforms of the enzyme have been identified on the basis of their biochemical properties, substrate selectivity, and gene products (Shih et al, 1999) . Monoamine oxidase-A preferentially oxidizes serotonin and noradrenaline while MAO-B preferentially oxidizes the trace amine phenethylamine. Dopamine is a substrate for both isoenzymes. The physiologic roles of MAOs are related to the nature of their substrates and selective inhibition of these isoforms is used to treat a variety of pathologic conditions. Inhibition of MAO-A is useful in the treatment of depression and anxiety disorders (Livingston and Livingston, 1996) while inhibition of MAO-B is more specifically used to treat neurodegenerative disorders such as Parkinson's disease (Cohen, 1990) .
The ability of MAOs to catabolize neurotransmitters has made these enzymes attractive candidates in the study of psychiatric and neurologic diseases as well as in the study of brain function. Many studies report apparent associations between abnormal platelet MAO activity and susceptibility to depression and suicidal behavior (Murphy and Weiss, 1972) , schizophrenia (Lewine and Meltzer, 1984) , Parkinson's disease (Jarman et al, 1993) , Huntington's chorea (Mann and Chiu, 1978) , alcoholism , and smoking . In these early studies, platelets were viewed as an accessible tissue to measure MAO activity, which was considered as an index of the enzyme activity in the brain. However, platelet MAO in human is exclusively of the MAO-B-type (Youdim, 1988) and provides no insight on the activity of the MAO-A-type.
Several lines of evidence indicate that abnormalities in brain MAO-A activity are involved in the pathogenesis of depressive illness and suicidal behavior. For instance, successful treatment of unipolar and bipolar depression is achieved using specific inhibitors of MAO-A such as clorgyline (Lipper et al, 1979) and moclobemide (Angst and Stabl, 1992) . Only a few studies have aimed at measuring MAO-A activity in the brain in relation to depression and these have provided conflicting results. While a significant elevation of MAO-A activity was found in the hypothalamus of depressed suicide victims (Sherif et al, 1991) , other studies showed no significant differences in MAO-A activity in any brain regions of depressed suicide victims when compared with controls (Mann and Stanley, 1984; Ordway et al, 1999) . Comparison of results obtained in the post-mortem brain has however been hampered by several confounding factors such as small sample sizes, insufficient matching criteria for controls, different methodology used to measure MAO activity, comorbidity between the use of medication, alcohol, or cigarette smoking, and the disease condition.
To circumvent these problems, several radioligands have been developed for in vivo imaging of MAO-A using positron emission tomography (PET) in living humans (Ametamey et al, 1996; Bottlaender et al, 2003; Fowler et al, 1987; Ohmomo et al, 1991 Ohmomo et al, , 1993 . Bergstrom et al (1997a) have reported on the synthesis of five different 11 C-labeled MAO-A inhibitors as potential radioligands for PET imaging of the enzyme. Among them, [ 11 C]-harmine is a bcarboline derivative, which is a competitive and reversible inhibitor of MAO-A with a K i of 5 nmol/L (Kim et al, 1997) . In vitro binding studies in rats have shown its binding is specific to MAO-A as it is inhibited by nanomolar concentrations of the selective MAO-A inhibitor clorgyline and only marginally affected by fairly selective MAO-B inhibitors such as deprenyl and pargyline (Bergstrom et al, 1997b) . In vivo PET studies in monkeys and humans have already showed its potential for imaging MAO-A (Bergstrom et al, 1997b, c) . In both species, [ 11 C]harmine showed favorable kinetics and displayed sensitivity to pretreament with selective MAO-A inhibitors such as moclobemide and esuprone.
Although these earlier studies clearly suggest that [ 11 C]-harmine may be a useful PET radioligand for the visualization and quantification of MAO-A in human, no kinetic modeling approach has ever been applied to quantify the binding of this radioligand in vivo.
The aim of the present study was to evaluate the prospect of using PET and [ 11 C]-harmine for quantification of MAO-A binding sites in the human brain. Regional brain uptake curves of [ 11 C]-harmine were quantified using kinetic modeling analyses based on either one-or two-tissue compartments, both at placebo condition and after treatment with moclobemide. Moclobemide is a short-acting, reversible, and selective MAO-A inhibitor that has proven to be efficacious in the treatment of major depression (Angst and Stabl, 1992) . In addition, the performance of the Logan graphical approach (Logan et al, 1990) was also evaluated to determine the simplest kinetic method for quantification of [ 11 C]-harmine binding data in routine clinical research.
Methods

Subjects
This study was approved by the Human Subjects Review Committee of the University of Toronto. Five healthy male volunteers free of neurologic or psychiatric diseases, with no past or current history of cigarette smoking, were recruited for the study. None of the subjects took central nervous system acting medication or drugs within 3 months before enrolment in the study. Subjects were asked not to drink alcohol the day before PET scanning and not to drink beverages with caffeine on the day of a PET scan. In all cases, written informed consent was obtained before participation. The age and weight of the subjects were 34711 years (range: 20 to 49 years) and 81713 kg (range: 70 to 100 kg), respectively (mean7s.d., n ¼ 5).
Each subject was scanned with PET and [ 11 C]-harmine on two different occasions using a double-blind, counterbalanced procedure. On one occasion, subjects were examined after 10 days treatment with oral placebo and on the other occasion, subjects were examined after 10 days treatment with moclobemide (Manerix s , Hoffmann-La Roche Limited, Mississauga, Canada). The washout period between treatment conditions (placebo versus moclobemide) was at least 8 weeks. When placed on moclobemide treatment, subjects received twice-daily dose (b.i.d.) of 150 mg moclobemide for 3 days and then 300 mg b.i.d. for 7 days. These daily doses of moclobemide are within the therapeutic dose range for moclobemide in most acute phase trials (Bonnet, 2003) and 300 mg b.i.d. is also the highest clinical dose that has a minimal risk for a hypertensive crisis. Moreover, a 10-day treatment period has been shown to be sufficient to reach steady-state plasma levels as the elimination half-life of moclomebide is approximately 2 h (Bonnet, 2003) . When placed on placebo treatment, the subjects received placebo tablets twice daily for 10 consecutive days. Drug or placebo intakes took place at 8 a.m. and at 7 p.m. daily. On day 10, PET scans of [ 11 C]-harmine binding were obtained 4 h after the last morning dose of either placebo or moclobemide. Subjects then continued to take 150 mg of moclobemide or placebo 3 days after the scan date as a taper.
Radiochemistry
[ 11 C]-methylation of normethylharmine was performed inside an HPLC sample loop using our previously described method (Wilson et al, 2000) . Briefly, indol-7-ol, 1.0 mg) was dissolved in dimethylformamide (DMF) (77 mL) and treated with tetrabutylammonium hydroxide solution (1 N in MeOH, 3 mL). This solution was loaded onto an HPLC injection loop (2 mL) on a Valco HPLC injector (Houston, TX, USA) valve in the load position. [ 11 C]iodomethane (produced as previously described; Wilson et al, 1994) was swept into the HPLC loop coated with precursor solution by a stream of N 2 gas (8 mL/min) at ambient temperature. When radioactivity peaked in the loop (3 to 4 mins), the flow of N 2 was stopped and the reaction allowed to proceed for 1 min at ambient temperature. The contents of the loop were then quantitatively injected onto the HPLC purification column by changing the position of the injection valve from the load to the inject position and the reaction mixture purified by semi-prep HPLC; Phenomenex Prodigy C 18 10m (250 Â 10 mm, 30% CH 3 CN/70% H 2 O þ 0.1 N NH 4 HCO 2 , pH 4, 7 mL/min). The desired fraction was collected, evaporated to dryness at 701C, and the residue taken up in 10 mL of sterile saline. The saline solution of [ 11 C]harmine was passed through a sterile 0.22 mm filter into a sterile, pyrogen-free bottle containing aqueous sodium bicarbonate (1 mL, 8.4%). An aliquot (100 mL) of the formulated solution was used to establish the radiochemical purity and specific activity of the final solution by analytical HPLC; Phenomenex Prodigy C18 10m (250 Â 4.5 mm, 30% CH 3 CN:70% H 2 O þ 0.1 N NH 4 HCO 2 , pH 4, 4 mL/min).
Positron Emission Tomography System
Studies were performed on a brain PET camera system Scanditronix GEMS 2048-15B, which measured radioactivity in 15 brain sections with a thickness of 6.5 mm each (Litton et al, 1990) . The intrinsic in-plane resolution of the reconstructed images is 5.5 mm full-width at halfmaximum. Transmission scans were acquired with a rotating 68 Ge source and used to correct the emission scans for the attenuation of the 511 keV photons through tissue and head support. Images were reconstructed by filtered back-projection using a Hanning 5 mm filter.
Positron Emission Tomography Studies
A thermoplastic mask was made for each subject and used with a head fixation system during the PET measure-ments. Cannulae were inserted in the radial artery for blood sampling, and in the controlateral arm antecubital vein for radioligand injection. A saline solution of 10.9 mCi (s.d. ¼ 1.0 mCi) of [ 11 C]-harmine at a specific radioactivity of 1,124 Ci/mmol (s.d. ¼ 203 Ci/mmol) was injected intravenously as a bolus and immediately flushed with 10 mL saline. Radioactivity in the brain was measured in a series of sequential frames of increasing duration (from 1 to 5 mins). The total time for measurement of radioactivity in the brain was 90 mins.
An automated blood sampling system (ABSS; Scanditronix, Uppsala, Sweden) was used to measure radioactivity in arterial blood during the first 10 mins of the experiment. It consists of a 30 cm long catheter line, a scintillation crystal detector to measure the concentration of radioactivity in blood, a peristaltic pump to draw arterial blood into the catheter, and a microprocessor datalogger. The pump speed was set at 2.5 mL/min and the concentration of radioactivity in the catheter was measured and stored every 2.5 secs.
At the same time and thereafter, manual blood samples were drawn at 5, 10, 15, 20, 30, 45, 60, or 70 and 90 mins after radiotracer injection. An aliquot of each blood sample was taken to measure radioactivity concentration in total blood. The remainder of blood was centrifuged (1,500g, 5 mins) and a plasma aliquot counted together with the total blood sample using a Packard Cobra II gamma counter cross-calibrated with the PET system. The blood-to-plasma ratios determined from the manual samples were used to correct the blood radioactivity time-activity curve measured by automatic sampling and to generate the plasma radioactivity curve. The remaining volume of each manual plasma sample was used to determine unchanged radioligand and its metabolites in plasma (as described in the next section). A metabolite corrected plasma curve was generated by the product of the two curves and was used as input function (C P (t), nCi/mL) for the kinetic and graphical analyses.
Determination of Radioactive Metabolites in Plasma
Plasma analysis of [ 11 C]-harmine was based on the column capture and switching methods developed by Luthra and Hilton (Hilton et al, 2000; Luthra et al, 1992) . Arterial blood samples were withdrawn at predefined times, centrifuged, and whole unadulterated plasma (0.5 to 5 mL) injected onto a small capture column packed with the OASISt resin (Waters, Milford, MA, USA). Highly polar metabolites and plasma proteins were eluted with 1% CH 3 CN in H 2 O (2 mL/min) through a coincidence flow detector (Bioscan Flow-Count). Less polar metabolites and [ 11 C]-harmine were then back-flushed onto an HPLC column (Phenomenex AquaC 18 , 5m, 150 Â 4.6 mm) and resolved using 30% CH 3 CN/70% H 2 O þ 0.1 N ammonium formate (AF). pH 4 as eluent (2 mL/min).
Regions of Interest
Each subject had a brain magnetic resonance imaging (MRI) examination. T 1 -weighted and proton density images were obtained on a General Electric Medical System Signa 1.5 T MRI scanner. Both T 1 -weighted and proton density images were acquired with spin-echo pulse sequences. Each subject's MRI scan was coregistered to the PET scan using Rview8/mpr realignment software (Studholme et al, 1997) .
Regions of interest (ROIs) for the cerebellar cortex, putamen, thalamus, prefrontal cortex, anterior temporal cortex, anterior cingulate cortex, and posterior cingulate cortex were drawn with reference to the coregistered MRI. Each ROI was drawn in two to four adjacent sections, in both hemispheres, and data from bilateral ROI were pooled to obtain the average radioactivity concentration in the volume of interest. Regional radioactivity was determined for each frame, corrected for decay, and plotted versus time.
Data Analysis
Compartmental kinetic analysis: Kinetic analysis of tissue data was performed with both a one-tissue (1CM) and a two-tissue compartment model (2CM). The 2CM includes: the radioactivity concentration of unchanged radioligand in plasma (C P ); the concentration of radioligand free and nonspecifically bound in tissue (C NS þ F ); and the concentration of radioligand specifically bound to receptor sites (C B ). The rate constants K 1 (mL/g min) and k 2 (min À1 ) describe the influx and efflux rates, respectively, for radioligand diffusion through the blood-brain barrier. The rate constant k 3 and k 4 describe the radioligand transfer between the nondisplaceable compartment (i.e., C NS þ F ) and the specific binding compartment (C B ). Model equations for the 2CM analysis of radiotracer binding to receptors are given by
k 4 (min À1 ) is the unimolecular receptor dissociation rate constant k off . The rate constant k 3 (min À1 ) is the product of the bimolecular association rate constant k on and the concentration of available receptors. The number of available receptors is the total number of receptors B max less the number of receptor-radioligand complexes, B R , and the number of receptor-inhibitor complexes, B I . Because all experiments were performed at tracer dose and high specific radioactivity, then: B R 5B max . At such conditions and when no drug is present in the brain, it follows that:
After treatment with an unlabeled drug I, k 3 is noted k 3 * and equals:
At high specific radioactivity, the radioligand binding potential (BP) corresponds to the ratio of the number of available receptors over K D and is expressed as a function of rate constants as (Mintun et al, 1984) : At placebo conditions:
After a drug treatment:
where K D , the radioligand equilibrium dissociation constant (nmol/L), equals to (k off /k on ).
The percentage of enzyme blockade achieved by a drug treatment can be defined as
Assuming competitive inhibition of the enzyme by the drug, the percentage of enzyme blockade can also be calculated by combining equations (5) and (6) and is defined as the percentage reduction of BP obtained after drug treatment as compared with the BP obtained at placebo conditions.
Note that calculation of % blockade using equation (8) assumes that the inhibitor-induced decrement in BP is because of a decrease in the number of available binding sites, with no change in K D . This does not exclude a parallel change in both k on and k off . Invalidation of this assumption would lead to a misestimation of % blockade. For instance, a decrease in k off with no parallel change in k on would lead to an underestimation of the % blockade as obtained with equation (8) when compared with that obtained with equation (7). The concept of distribution volume (DV; mL g À1 ) is also frequently used in tracer kinetics to estimate binding site density. The total DV (DV T ) has the advantage of being a more stable parameter than the individual kinetic parameters determined from compartmental analysis (Carson et al, 1993; Koeppe et al, 1991) . The DV T of a radioligand in a tissue is the volume of tissue in which the radioligand would have to distribute to reach a concentration equal to that in the plasma. It is defined as:
where DV NS þ F corresponds to the radioligand DV in the free and nonspecifically bound compartment and DV B to the DV in the specifically bound compartment DV NS þ F and DV B can be expressed in terms of the kinetic rate parameters as follows:
Note that after treatment with an unlabelled drug I, the term k 3 in equation (11) should be replaced by the term k 3 *. Assuming that DV NS þ F is similar at placebo and at drug treatment conditions, the percentage of drug-induced receptor blockade can be defined as the percentage reduction of DV B obtained after drug treatment as compared with the DV B obtained at placebo conditions.
Note that, as in equation (8), calculation of % blockade using equation (12) assumes that the inhibitor-induced decrement in DV B is because of a decrease in the number of available binding sites, with no change in K D . A simplification of the 2CM into a 1CM can be made by assuming that the concentrations C NS þ F and C B equilibrate rapidly and are combined in one single compartment. The total distribution volume for the 1CM is noted as DV 0 and is given by:
Nonlinear least-square fitting: Nonlinear least-squares fitting (NLSF) analyses using the Marquardt algorithm (Marquardt, 1963) and based on the 1CM and the 2CM were applied to the time-activity curves for regional [ 11 C]harmine uptake. The contribution of fractional blood volume in the brain was fixed at 5% for all ROIs (Phelps et al, 1979) . For each subject, the time delay between the plasma arterial input function and the brain time-activity data was estimated by fitting a whole-brain slice at the level of the striatum to an unconstrained 2CM using the 90 mins data set. However, it was difficult to characterize this delay with reasonable accuracy when using a 2CM, 5 parameters configuration. To estimate the delay, the delay value was thus increased gradually, using 1 sec increments, to minimize the residual sum of squares (RSS) of the whole-brain curve. The delay parameter value, which gave the least RSS on the fitted whole-brain curve, was used in the subsequent analyses where regional timeradioactivity curves were fitted. Different model configurations were used for analysis of [ 11 C]-harmine (Table 1) . Method A was based on the 1CM and NLSF analyses were performed to estimate K 1 , k 2 0 , and DV 0 . Method B was based on the 2CM and NLSF analyses were performed to estimate the four rate constants K 1 , k 2 , k 3 (or k 3 *), and k 4 . To improve the stability of the fits, two other fitting strategies were tested. Both were based on the 2CM. Method C assumed the ratio K 1 /k 2 to be similar between regions. Nonlinear least-squares fitting analyses were accordingly performed by fitting simultaneously data from all regions and guided by the constraint of finding a K 1 /k 2 value common to all regions. A second approach, Method D, was used for the [ 11 C]-harmine placebo scans only. For each subject, this method consisted to fix the K 1 / k 2 ratio in the placebo study to the value obtained in the moclobemide study using Method C. This method was based on the assumption that DV NS þ F is similar under both treatment conditions. Three rate constants, K 1 , k 3 (or k 3 *), and k 4 (with k 2 ¼ K 1 /DV NS þ F ) were estimated. Nonlinear least-squares fitting analyses were performed using the dedicated software PMOD V2.4 (PMOD Technologies Ltd, Zurich, Switzerland).
Simplified Method of Analysis
In addition to the kinetic modeling approach, [ 11 C]harmine binding was quantified using the linear graphical approach described by Logan et al (1990) for the analysis of reversible radioligand binding. A plasma input function corrected for the presence of labeled metabolites (C P (t)) was used. The ratio R t 0 ROIðt 0 Þdt 0 =ROIðtÞ was plotted versus R t 0 C P ðt 0 Þdt 0 =ROIðtÞ, with ROI(t) describing radioactivity in a defined ROI as a function of time. The DV T of the radioligand in that ROI was determined from the linear portion of the plot obtained.
Statistics: Goodness-of-fit was evaluated using both the Akaike Information Criterion (AIC; Akaike, 1974) , the Model Selection Criterion (MSC). Higher AIC and lower MSC values were indicative of a better fit. In addition, models of higher complexity were also successively compared using an F-test to determine whether goodness-of-fits was sufficiently improved to justify the choice of a model with a higher number of parameters (Landaw and DiStefano, 1984) . Statistical significance using the Ftest was assumed for P values superior or equal to 0.05.
The standard error of the parameters was given by the diagonal of the covariance matrix (Carson, 1986) , expressed as percentage of the parameter value (coefficient of variation, %COV), and used to assess the parameter identifiability by the NLSF procedure. Calculation of %COV was possible only for fitted parameters. For derived parameters such as k 3 /k 4 and DV T , the s.d. of the mean (n ¼ 5 subjects) was calculated, expressed as percentage of the mean derived parameter value, and used as an indication of the degree of intersubject variability of the parameter (%VAR ¼ s.d. Â 100%/mean).
Results
Plasma Analysis
HPLC analysis of a plasma sample could be completed in less than 8 mins allowing multiple time points to be analyzed despite the short half-life of carbon-11. [ 11 C]harmine was rapidly metabolized with 450% of the radioactivity in the plasma attributable to polar metabolites after 20 mins. At placebo conditions, the fraction of 73%, and 11%75% at 5, 10, 20, 30, 45, 70 , and 90 mins, respectively. After moclobemide treatment, [ 11 C]-harmine metabolism was faster than that measured at placebo treatment, with 94%74%, 71%713%, 24%78%, 18%7 6%, 12%74%, 9%72%, and 11%75% at 5, 10, 20, 30, 45, 70, and 90 mins, respectively. In both treatment conditions, all metabolites were significantly more polar than the parent compound and thus unlikely to pass the blood-brain barrier. Figure 1 shows representative curves obtained in the same subject for unmetabolized [ 11 C]harmine in the plasma under placebo and moclobemide treatment conditions. As shown in Figure 1 , the concentration of unmetabolized [ 11 C]-harmine in plasma peaked at higher levels after moclobemide treatment when compared with placebo conditions.
Kinetic Analyses
Placebo studies: Characteristic time-activity curves obtained after intravenous injection of [ 11 C]-harmine in one subject are shown in Figure 2A . At placebo conditions, the highest radioactivity concentration was observed in the thalamus, intermediate levels were observed in striatum and cortical regions, and lowest levels of radioactivity were observed in the cerebellum. Figure 2B shows regional tissue to plasma radioactivity ratio in the corresponding subject. With few exceptions, transient equilibrium between tissue and plasma levels of radioactivity was obtained after 30 mins of data acquisition in all regions and all subjects. As illustrated on Figure 3A , a 1CM configuration failed to describe the [ 11 C]-harmine time-activity data. Adding a second tissue compartment (Method B) significantly improved the fits in all regions and all subjects when compared with the 1CM as assessed with AIC and MSC values ( Table 2) as well as F-statistics. F-statistics for each ROI time-activity curve and each subject were in the range of F ¼ 5.7 to 200.4 and F 2,15 was significant at Pr0.05 for FZ3.68. Despite this, DV T values obtained with a 1CM or a 2CM configuration were close ( Figure 4A ): a 1CM provided DV T values that were, on average, approximately 5% lower than those obtained with a 2CM. This difference was observed in all brain regions examined.
An unconstrained 2CM (Method B) provided reasonable identification of K 1 and k 4 with mean %COVs of 6.2% and 13.7%, respectively, but provided poor identification of k 2 and k 3 , as exhibited by the large standard errors in parameter estimates (Table 3) . As a consequence, the k 3 / k 4 ratios were highly variable between subjects (Table 3) and the rank order of regional k 3 /k 4 did not correlated with the known concentration of MAO-A in brain as measured by in vitro autoradiography (cerebellumofrontal cortex-Eputameno temporal cortexEcingulateothalamus; Saura et al, 1992 Saura et al, , 1996a . In contrast, the rank order of DV B values was in accordance with the known Figure 2 Representative [ 11 C]-harmine time-activity curves obtained at placebo conditions for (A) regional brain radioactivity and (B) tissue/plasma ratio.
PET quantification of [ 11 C]-harmine in humans N Ginovart et al distribution of MAO-A in the brain, with mean regional values ranging from 10.5 in the cerebellum to 22.2 in the thalamus, with putamen and cerebral cortices showing intermediate values (Table 3) . DV B values were estimated with high precision, as attested by a mean %COV of 4.4% (range: 1% to 7%). DV T values were also estimated with high precision (mean %COV ¼ 2%; range: 1% to 5%) and the rank order of DV T values also paralleled the rank order of MAO-A density in brain. This could be expected as a major proportion (86%76% in average across regions; range: 82% to 92%) of DV T was accounted for by specific binding. Methods C and D significantly improved the identifiability of k 3 and k 4 estimates (Table 4 ) when compared with Method B (Table 3) as shown by the lower %COV obtained with the two former methods. Despite this, goodness-of-fits was not statistically improved by using Method C or D when compared with Method B as assessed with AIC and MSC (Table 2) . F-statistics indicated that Methods C and D slightly worsened goodness-of-fits when compared with Method B but this was not statistically significant for most fits.
At placebo conditions, Method C provided k 3 /k 4 values in accordance with the known regional densities of MAO-A in the brain but data were affected by a large intersubject variability (mean %VAR ¼ 34.872.2; Table 4 ). DV B and DV T values estimated with Method C were similar and not significantly different than those estimated with Method B.
Method D provided excellent estimations of k 3 /k 4 values with a %COV of 2.871.5 and a %VAR of 15.273.2 (Table  4 ). Despite this superiority in determining BPs, the mean DV T and DV B values obtained with Method D were very close to those estimated with Methods B and C (see Tables  3 and 4 ). In addition, DV T values obtained using the three methods (B, C, and D) were not significantly different than those derived from the Logan approach ( Figure 4A ). DV T values obtained with each 2CM method (irrespective of whether it was constrained on unconstrained) significantly correlated with DV values obtained with the Logan approach and this is illustrated in Figure 5 with Method B as an example (slope ¼ 1.05; R ¼ 0.98; Student's t-test: Po0.001).
A comparison between the mean regional DV B values as measured in our experimental conditions using [ 11 C]harmine and Method D and the mean [ 3 H]Ro 41-1049 specific binding values reported in vitro in corresponding regions of the rat brain is shown in Figure 6 Moclobemide studies: As observed at placebo conditions, a 2CM produced better fits to the data than a 1CM configuration ( Figure 3B ; Table 2 ). F-tests also indicated that a 2CM significantly better fit the data than a 1CM for 31 of the 35 regional binding curves. DV T values obtained with a 1CM were, in average, 19% lower than those obtained with a 2CM (Figure 4B) .
A 2CM (Method B) allowed reasonable identification of K 1 and k 2 but both k 3 * and k 4 values were poorly identified (Table 3) . DV B and DV T values were estimated with good precision and were significantly reduced in all regions when compared with placebo (repeated measures ANO-VA: F 1,34 ¼ 481.6; Po0.001 for DV B and F 1,34 ¼ 368.7; Po0.001 for DV T ). Using data obtained at both placebo and moclobemide conditions, DV T and DV B values estimated with an unconstrained 2CM were highly correlated (Figure 7) . The percentage of moclobemideinduced DV B reduction (which is a reflection of the percentage of MAO-A blockade-see equation (12) Values are mean7s.d. of 5 experiments. %COV corresponds to the standard error of parameter estimated by the nonlinear least-squares fitting procedure, is expressed in percent of the parameter value and is given as an index of the parameter identifiability. %VAR corresponds to the inter-subject variability in the parameter estimates.
thalamus. DV T values reduction ranged from 43%78% in the cerebellum to 66%76% in the thalamus. Methods C fits did not statistically modify goodness-offits when compared with Method B as assessed using AIC and MSC (Table 2) . F-tests also indicated that Method C was not statistically different from Method B in most fits. K 1 values estimated using Method C at moclobemide conditions were significantly lower than those obtained at placebo (repeated measures ANOVA: F 1,34 ¼ 22.9; Po0.001; Table 4 ). However, DV NS þ F values were not significantly different between the two conditions (2.747 0.84 and 3.5170.51 at placebo and moclobemide conditions, respectively; Student's t-test: P40.05; Table 4 ), suggesting that free and nonspecific binding were similar at placebo and moclobemide conditions. This was the main rationale for using K 1 /k 2 values obtained in the moclobemide studies to fit the placebo data (i.e., Method D). When compared with k 3 values obtained with Method D at placebo conditions, there were significant reductions in the values of k 3 * in the moclobemide studies (Table 4) . Surprisingly, k 4 values were also significantly reduced by moclobemide treatment by 34% on average (repeated measures ANOVA: F 1,34 ¼ 47.2; Po0.001; Po0.001; see Method C in Table 4 ). Fits of the moclobemide data were attempted by fixing k 4 to the values obtained in the placebo studies. This procedure worsened the data fits in all subjects (data not shown). Similarly, acceptable fits of the placebo data could not be obtained when k 4 was fixed to the value obtained in the moclobemide studies, suggesting that k 4 was truly different between the two sets of studies.
The percentage blockade of MAO-A calculated using DV B and BP values were identical (calculations were performed using Methods D and C in the placebo and moclobemide studies, respectively) and ranged from 64% 77% in the cerebellum to 79%74% in the thalamus. This could have been predicted as Methods D and C assumes that K 1 /k 2 values are similar between brain regions at placebo and moclobemide conditions. Similarly, the percentage blockade of MAO-A calculated using DV B values obtained with an unconstrained 2CM gave values that were, in average, only 2.2% lower (range: À4.1% to þ 1.4%) than those estimated with BP values (Figure 8 ; repeated measures ANOVA: F 1,34 ¼ 47.2; P40.05).
Discussion
The primary goal of this study was to evaluate methods to obtain reliable estimates of MAO-A density from the analysis of [ 11 C]-harmine brain uptake curves in humans using PET. At placebo conditions, the regional distribution of [ 11 C]-harmine uptake was concordant with the known densities of MAO-A sites in the brain. The highest levels of radioactivity were observed in the thalamus, intermediate levels were observed in the striatum and cortical regions, whereas lowest levels of radioactivity were observed in cerebellum. At moclobemide conditions, the relative regional differences in [ 11 C]-harmine uptake levels were markedly reduced, indicating a substantial blockade of the MAO-A sites.
However, the peak levels of radioactivity in the brain as well as in the plasma were higher at moclobemide than at placebo conditions. Monoamine oxidase-A is abundant in peripheral organs such as the liver, kidneys, heart, lungs, and duodenum in humans (Fowler et al, 2003; Saura et al, 1996b) . Moclobemide-induced inhibition at these peripheral sites likely explains the increased bioavailability of [ 11 C]harmine in the plasma and, therefore, the increased net amount of radioactivity that enters the brain when compared with placebo conditions. Kinetic analyses of [ 11 C]-harmine brain uptake data showed that a 2CM configuration provided significantly better fits than a 1CM configuration. This was true both at placebo and moclobemide treatment conditions and for all criteria (AIC, MSC, and F-statistics). Despite this statistical superiority of a 2CM in describing [ 11 C]-harmine time-activity data, the difference in DV T values obtained between a 1CM and a 2CM was small, especially at placebo conditions. This likely indicated a poor separation of the free and nonspecifically bound and specifically bound compartments. This view was supported by the poor identification of k 3 and k 4 using an unconstrained 2CM. However, the statistically better fits obtained with all 2CM configurations as compared with the 1CM indicate that, although the differences were small, DV T values should be more accurately determined with inclusion of a second tissue compartment.
A 2CM configuration provided good identification of K 1 at both treatment conditions. However, K 1 values were significantly reduced at moclobemide conditions when compared with placebo, a result suggesting a decreased cerebral blood flow (CBF) during moclobemide treatment. There is a large body of evidence showing that serotonin and norepinephrine, the two major MAO-A substrates that are known to be elevated during moclobemide treatment (Nair et al, 1993) , are potent cerebral vasoconstrictors and reduce CBF (Grome and Harper, 1983; Szabo et al, 1983) . Stimulations of the dorsal raphe nucleus, from which 90% of the serotonin innervation of the brain originates, have also been shown to decrease CBF in a large number of brain structures (Bonvento et al, 1989) . Finally, studies in MAO-A-deficient mice, which show chronic elevation of serotonin and norepinephrine in the brain, also showed decreased blood flow in several brain regions when compared with their wild-type counterparts (Holschneider et al, 2000) . In light of these data, it can be postulated that the decreased K 1 values observed during moclobemide treatment reflect vasoconstrictor-induced decreases in CBF resulting from increased brain levels of serotonin and norepinephrine.
An unconstrained 2CM yielded individual parameter values for k 2 , k 3 , and k 3 * that were highly variable and BP values that did not correlate with the known densities of MAO-A in the brain. In contrast, DV B and DV T values were estimated with high precision at both placebo and moclobemide conditions. Although DV B and DV T includes information both on radioligand delivery and binding to specific receptor sites, at equilibrium they should be independent of tracer delivery and give an index of receptor site density (Logan et al, 1994) . This view was supported by the observation that the rank of order of both parameter values correlated well with the typical rank of order of MAO densities found in both the rat and human brain post mortem (Saura et al, 1996a (Saura et al, , 1992 . It was further supported by the observation that moclobemide treatment induced 43% to 66% and 63% to 82% reductions in DV T and DV B values, respectively, when compared with placebo conditions, thus suggesting that variations in these parameters, and more specifically in DV B , are more likely to reflect variations in receptor numbers than variations in nonspecific binding.
The difficulty in deriving reliable individual estimates for k 3 , k 3 *, and k 4 from a 2CM four parameters configuration while obtaining stable DV T has already been reported for other radioligands (Abi-Dargham et al, 1994; Koeppe et al, 1996) . By imposing constraints on the fitting procedure, more consistent estimates of receptor binding parameters were obtained. One approach that is commonly used consists of constraining the levels of free and nonspecific binding in receptor-rich regions to the level measured in a brain region, often referred as 'reference region', devoid of specific binding sites (Farde et al, 1989; Koeppe et al, 1991) . This approach could not be used with [ 11 C]-harmine as, in accordance with in vitro measurements showing an ubiquitous distribution of MAO-A in the brain (Saura et al, 1992 (Saura et al, , 1996a , no reference region could be identified. Another approach consists of constraining parameter values in the model that are predicted not to have large variations between brain regions. Method C, which assumes that K 1 /k 2 is similar in all brain structures, has already been shown to increase substantially the identifiability of kinetic parameters (Buck et al, 1996; Ginovart et al, 2001) . Method C substantially reduced the COVs on k 3 and k 4 estimates when compared with Method B and gave regional BP values in accordance with the known distribution of MAO-A in the brain (Saura et al, 1996a (Saura et al, , 1992 . Method D consisted of estimating the free and nonspecific binding from the blocking studies and to subsequently use that estimate in the analysis of placebo data. This approach has been successfully used to improve the kinetic parameter estimation of radioligands such as [ 18 F]spiperone and [ 11 C]flumazenil (Price et al, 1993) . Method D also yielded BP values in accordance with physiologic expectation and was the method providing the highest accuracy and lowest interindividual variability in BP estimates. For that reason, we consider it to be the method of choice for derivation of [ 11 C]harmine BPs at placebo conditions. If no data are available at drug-treatment conditions and Method D is thus not applicable, then Method C can be used to estimate BPs.
All three 2CM-based methods (Methods B, C, and D) gave similar estimates for DV T and DV B and both parameters were estimated with high reliability. In addition, DV T values estimated with the three methods were highly correlated and not significantly different from those estimated with the Logan approach. Thus, DV T and DV B appear to be valuable outcome measures for clinical studies as they are determined with high level of precision and are not biased by potential subject differences in blood flow or peripheral clearance. Moreover, the high correlation between DV T and DV B values obtained at both placebo and moclobemide conditions suggests that nonspecific binding of [ 11 C]-harmine was similar not only across brain regions but also between conditions. As MAO-A blockade increased, DV T and DV B decreased, increasingly approaching DV NS þ F values. As predicted by equation (9), which describes DV T as a linear function of DV B , the plot of DV T as a function of DV B should have a slope equal to unity and a y intercept of DV NS þ F . Linear regression across all subjects, all regions, and across both treatment conditions yielded values of 3.8 mL/g for DV NS þ F . This value is in close agreement with the value obtained at moclobemide conditions using Method C, which yielded a mean DV NS þ F value of 3.57 0.5 mL/g (Table 4 ). When linear regression was performed using all subjects and all regions but only data acquired at placebo conditions, it yielded a DV NS þ F value of 3.1 mL/g (data not shown). Here again, this indirect way of deriving DV NS þ F estimate using an unconstrained 2CM (i.e., Method B) yielded a DV NS þ F value that was close to that determined by Method C at placebo conditions (2.74 70.84; Table 4 ). The consistencies between the DV NS þ F values extrapolated from the regression data obtained with Method B and describing DV T as a function of DV B and those directly estimated by the model by Method C thus support the model simplifications made in this latter method and further strengthen the case for its use in clinical studies.
Treatment with moclobemide induced substantial reductions in k 3 , DV B , and DV T values when compared with placebo. Nonspecific binding was relatively unaffected by the pharmacological treatment as shown by the similar DV NS þ F values obtained using Method C at placebo and moclobemide conditions. In contrast, the dissociation rate constant k 4 for [ 11 C]-harmine was substantially decreased after moclobemide treatment when compared with placebo. Such a decrease was unexpected as k 4 , which equals k off , is usually considered not to vary between experimental conditions. Investigations where a compartmental modeling approach has been applied to obtain the in vivo kinetic parameter estimates of a radioligand both at drugfree and at drug-treatment conditions are scarce. While the assumption of a constant k 4 is reasonable when comparing different brain regions in a same subject and at similar experimental conditions, k 4 may vary with pharmacological treatment. Two explanations can be proposed for a decreased k 4 under moclobemide treament. One explanation is the existence of a nonspecific binding compartment that turns over relatively slowly because of nonspecific interactions with proteins, lipids or other receptor compartment. Because a major proportion of the specific binding compartment is blocked under moclobemide conditions, this slow kinetic nonspecific binding compartment would become more prominent in the moclobemide than in the placebo studies, and this would be reflected in an apparent decrease in k 4 . Another possibility is that the effect of moclobemide on k 4 is indicative of an allosteric modulation of MAO-A by the drug. Negative allosteric modulators are known not only to decrease radioligand association on the orthosteric site but also to decrease their dissociation rate (Holzgrabe and Mohr, 1998) . Although the mechanism of MAO-A inhibition by moclobemide is not fully clear yet, several studies suggest that moclobemide may act through mixed competitive and noncompetitive inhibition of the enzyme (Da Prada et al, 1989; Waldmeier, 1985) . The decrease in k 4 obtained after moclobemide treatment could reflect this noncompetitive interaction. Assuming that this decrease in k 4 (i.e., k off ) was accompanied by a similar decrease in k on (and that K D was thus unaffected; see assumptions for equations (8) and (12)), the percentage of MAO-A blockade induced by clinical doses of moclobemide was substantial, ranging from 64% in the cerebellum to 79% in the thalamus. Because our data cannot rule out the possibility of a decrease in k 4 with no parallel change in k on , it is thus possible that the percentage of MAO-A blockade achieved by moclobemide is somewhat even higher than 64% to 79%. This substantial level of MAO-A blockade induced by moclobemide further supports the specificity and suitability of [ 11 C]-harmine for quantifying MAO-A binding sites in vivo using PET.
In summary, kinetic analyses showed that a 2CM best describes [ 11 C]-harmine kinetics, although it showed poor identifiability of BP values. However, it provided stable and reliable estimates for [ 11 C]harmine regional DV B and DV T that were consistent with the known distribution of MAO-A densities in the human brain. Reduction in the complexity of the 2CM, either by fixing or by coupling DV NS þ F value during the fits, allowed the derivation of more stable estimates for BPs but neither improved goodness-offits nor improved reliability in DV T and DV B estimates when compared with an unconstrained 2CM. Under ideal conditions, measures of BP should be preferred as index of binding density because they vary directly with B max . However, as these measures are estimated with uncertainty for [ 11 C]-harmine, we would recommend using DV B as index of binding site density. Because the variability and identifiability of DV B values estimated with all 2CM methods were similar, an unconstrained 2CM configuration should be selected for determination of this parameter as outcome measure as this method has the advantage of computational simplicity. As an alternative, DV T could also be selected as outcome measure. Indeed, DV T values estimated with all 2CM configurations were remarkably stable, highly correlated, and not significantly different from those estimated with the Logan method. This latter method of analysis is even simpler as it only involves a simple linear regression of the data.
The results of the present study thus support the suitability of using [ 11 C]-harmine for the quantitative evaluation of MAO-A densities in human using PET. The stability and reliability of DV B values obtained for an unconstrained 2CM, together with the computational simplicity associated with this method, support the use of DV B as an appropriate outcome measure for [ 11 C]-harmine.
